Table 6.
Ongoing Clinical Studies for Selinexor and Belantamab (Source: Clinicaltrials.gov)
| S.N | Title | Status | NCT Number |
|---|---|---|---|
| 1 | Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy. | Recruiting | NCT04519476 |
| 2 | Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma | Active, not recruiting | NCT02186834 |
| 3 | Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma | Recruiting | NCT02780609 |
| 4 | A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma | Recruiting | NCT04414475 |
| 5 | Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | NCT02199665 |
| 6 | Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma | Active, not recruiting | NCT03110562 |
| 7 | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma | Recruiting | NCT03589222 |
| 8 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Recruiting | NCT02343042 |
| 9 | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Relapsed Refractory Multiple Myeloma, The SCOPE Trial | Recruiting | NCT04764942 |
| 10 | A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma | Recruiting | NCT03944057 |
| 11 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | Recruiting | NCT03732703 |
| 12 | Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Recruiting | NCT04162210 |
| 13 | A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Hepatic Function | Recruiting | NCT04398680 |
| 14 | A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function | Recruiting | NCT04398745 |
| 15 | A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Active, not recruiting | NCT04177823 |
| 16 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | Recruiting | NCT04802356 |
| 17 | Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | Recruiting | NCT04091126 |
| 18 | Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma | Recruiting | NCT04484623 |
| 19 | Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | NCT04246047 |
| 20 | Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma | Recruiting | NCT04808037 |
| 21 | Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma | Recruiting | NCT04680468 |
| 22 | Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5) | Recruiting | NCT04126200 |
| 23 | A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody | Active, not recruiting | NCT03525678 |
| 24 | To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Recruiting | NCT03544281 |
| 25 | Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (RRMM) | Active, not recruiting | NCT03848845 |
| 26 | An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | Recruiting | NCT03828292 |
| 27 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | Recruiting | NCT02343042 |
| 28 | Myeloma-Developing Regimens Using Genomics (MyDRUG) | Recruiting | NCT03732703 |